Optic nerve sheath ultrasound for the detection and monitoring of raised intracranial pressure in tuberculous meningitis

Joseph Donovan\textsuperscript{1,2}, Pham Kieu Nguyet Oanh\textsuperscript{3}, Nicholas Dobbs\textsuperscript{4}, Nguyen Hoan Phu\textsuperscript{2,5}, Ho Dang Trung Nghia\textsuperscript{3,6}, David Summers\textsuperscript{4}, Nguyen Thuy Thuong Thuong\textsuperscript{1,2}, Guy E. Thwaites\textsuperscript{1,2}
on behalf of the Vietnam ICU Translational Applications Laboratory (VITAL) investigators*

1. Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam
2. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom
3. Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
4. Department of Clinical Neuroscience, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
5. Vietnam National University School of Medicine, Ho Chi Minh City, Vietnam
6. Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam

* Members listed in the supplementary appendix

Corresponding author: Joseph Donovan

Email: jdonovan@oucru.org. Phone: +84839239207. Fax: +84839238904

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Summary: Neurological complications of tuberculous meningitis often elevate intracranial pressure. Increased optic nerve sheath diameter was associated with increased disease severity, brain imaging abnormalities, and increased death by 3 months. Optic nerve sheath diameter ultrasound may aid monitoring in tuberculous meningitis.
Abstract

Background: Neurological complications of tuberculous meningitis (TBM) often lead to raised intracranial pressure (ICP) resulting in high morbidity and mortality. Measurement of optic nerve sheath diameter (ONSD) by point-of-care ultrasound may aid in the identification and management of raised ICP in TBM.

Methods: From June 2017 to December 2019, 107 Vietnamese adults with TBM, enrolled in the ACT HIV or LAST ACT trials (NCT03092817; NCT03100786), underwent ONSD ultrasound at one or more of days 0, 3, 7, 14, 21 +/- 30 after enrolment. Demographic data, TBM severity grade, HIV co-infection status, and clinical endpoints by 3 months were recorded. ONSD values were correlated with disease severity, baseline brain magnetic resonance imaging or computed tomography imaging, cerebrospinal fluid parameters and clinical endpoints.

Results: 267 ONSD ultrasound scans were performed in 107 participants over the first 30 days of treatment, with measurements from 0.38 - 0.74cm. Paired baseline ONSD and brain imaging were performed in 63 participants. Higher baseline ONSD was associated with more severe disease and abnormal brain imaging (abnormal imaging 0.55cm vs 0.50cm normal imaging, p=0.01). Baseline median ONSD was significantly higher in participants who died by 3 months (0.56cm [15/72]) vs. participants who survived by 3 months (0.52cm [57/72]), p=0.02. Median ONSD was higher at all follow up time points in participants who died by 3 months.

Conclusions: Higher ONSD was associated with increased disease severity, brain imaging abnormalities, and increased death by 3 months. ONSD ultrasound has a potential role as a non-invasive and affordable bedside tool for predicting brain pathology and death in TBM.

Key words: Optic nerve sheath, ultrasound, tuberculous meningitis, intracranial pressure
**Background**

Tuberculous meningitis (TBM) accounts for 2-5% of all TB cases. Death results in up to 50% of those with TBM,[1–4] largely due to severe neurological complications which are hard to predict and difficult to manage. Hydrocephalus, brain infarcts, and enlarging tuberculomas all contribute to the devastating morbidity and poor outcomes of TBM. These complications may cause raised intracranial pressure (ICP), which can quickly lead to coma and death. Early recognition and management of raised ICP is vital in order to minimise intracerebral damage and maintain cerebral perfusion.

Invasive intracranial monitoring is the gold standard for measuring ICP in brain injury. However, invasive monitoring, involving device insertion into the central nervous system, requires specialists in a neurocritical care setting. Invasive ICP monitoring is not available to most individuals with TBM, who primarily reside in settings with limited health resources. Use of minimally- or non-invasive methods for raised ICP detection is common in brain infection (table 1). Clinical assessment has limitations; monitoring performed after neurological deterioration may prove too late in TBM. Lumbar cerebrospinal fluid (CSF) opening pressure, or counting CSF drops over time, are often used as surrogate markers of ICP. However, pressure may not be evenly distributed throughout subarachnoid spaces, and few data support a positive correlation between lumbar CSF opening pressure and ICP. [5,6] Fundoscopy is a low cost technique used to visualise changes in the optic nerve head - papilloedema - that can indicate raised ICP. Yet fundoscopy relies upon operator clinical skill and experience, and upon prior pupillary dilation to obtain satisfactory views. Importantly, papilloedema does not develop immediately after ICP elevation, limiting its use in acute monitoring.

Safe, cheap and accessible monitoring, with high sensitivity for raised ICP detection, has the potential to enhance TBM management globally. The optic nerve, forming part of the central nervous system (CNS), is surrounded by a dural sheath that is distensible in its retrobulbar segment when ICP is elevated. Changes in optic nerve sheath diameter (ONSD) due to raised ICP occur in
seconds.[7] Under ultrasound imaging the optic nerve appears hypoechogenic, surrounded by echogenic pia mater, hypoechogenic subarachnoid space, and then hyperechogenic dura mater and periorbital fat. A distended optic nerve sheath suggestive of elevated ICP is shown in figure 1.[8] ONSD ultrasound is safe, requires little training,[9] and can be performed in less than five minutes. Studies in healthy individuals suggest that ONSD varies by ethnicity,[10–15] however ONSD does not appear to vary with adult age, gender, or body mass index,[14] with waistline, head circumference, blood pressure or pathological subtype,[16] or side of eye measured.[13] Intra-operative and inter-operative variabilities are acceptably low.[14] Meta-analyses confirm correlation between ONSD and invasively measured ICP,[17–19] although studies of Europeans with non-infective brain pathology have predominated. Reports of ONSD ultrasound in brain infection are scarce, with only a single peer reviewed publication in TBM;[20] 25 Indian adults with suspected TBM based on consistent magnetic resonance imaging (MRI) appearances (n=25, mean ONSD 5.81mm) were compared with a control group where individuals lacked MRI appearances of TBM or papilloedema on fundoscopy (n=120, upper limit of normal for ONSD 4.37mm).[20] Larger studies are required to further investigate the role of ONSD ultrasound in TBM.

We sought to answer the following questions: does elevated ONSD correlate with HIV status, TBM severity grade, or clinical endpoints by 3 months? Does elevated ONSD correlate with TBM brain imaging abnormalities or features of raised ICP? Can an ONSD cut-off value predict TBM brain imaging abnormalities or features of raised ICP? And how do ONSD values change during the first 30 days of anti-TB chemotherapy?

Methods

Participants

We performed a prospective study of ONSD ultrasound in Vietnamese adults with TBM enrolled in the ACT HIV[21] or LAST ACT[22] clinical trials (Clinicaltrials.gov, NCT03092817 and NCT03100786, respectively). These two on-going multicentre randomised placebo-controlled trials are assessing
adjunctive corticosteroid therapy for the treatment of TBM in HIV co-infected adults, and in HIV uninfected adults stratified by leukotriene A4 hydrolase (LTA4H) genotype, respectively. Enrolled participants were ≥18 years old, with clinical evidence of TBM based on consistent clinical and CSF findings, with or without HIV co-infection, and treated at the Hospital for Tropical Diseases (HTD) in Ho Chi Minh City, Vietnam. Patients were excluded if an additional brain infection to TBM was suspected, >6 consecutive days of anti-TB chemotherapy or systemic corticosteroid were received, or corticosteroids were mandatory or contraindicated. Informed consent was obtained from all participants or from a relative if the participant was incapacitated. Ethical approvals for ACT HIV and LAST ACT, which included ethical approval for ONSD ultrasound, were obtained from the Oxford Tropical Research Ethics Committee (36-16 and 52-16, respectively), the ethical committee of HTD (14/HDDD and 37/HDDD, respectively) and the Vietnam Ministry of Health (108/CN-BDGDD and 151/CN-BDGDD, respectively). Permission to publish these study data was obtained by the chair of the respective Trial Steering Committees.

Clinical data

Demographic data (age, gender), baseline Modified Research Council (MRC) TBM severity grade[23] and HIV status were recorded. Final TBM diagnoses (definite, probable, possible) were assigned following the published uniform case definition for TBM (supplementary material 1).[24] Death and new neurological complications by 3 months were recorded. Neurological complications were defined as a fall in Glasgow coma score (GCS) of ≥ 2 points for ≥ 48 hours, a focal neurological sign, seizure, cerebellar signs, coma, or cerebral herniation.

Baseline brain MRI (T1, T1 contrast, T1 contrast fluid attenuated inversion recovery, and T2 weighted sequences) was performed when safe to do so. Computed tomography (CT) imaging was performed when MRI was not possible. Hydrocephalus, number and location of cerebral infarctions and tuberculomas, meningeal enhancement, and raised ICP features were recorded. Brain imaging was
reported by an independent neuroradiologist, blind to ONSD data, following a standard template (supplementary table 1).

For analysis, brain imaging was classified as abnormal if it contained one or more of the following: hydrocephalus, cerebral infarction(s), tuberculoma(s), meningeal enhancement and/or features of raised ICP. Correlation between cross sectional imaging findings and raised ICP is limited until it is particularly severe. However, a binary data point relating to imaging findings suggestive of raised ICP was recorded for each case. This was based on the global impression of the reporting neuroradiologist, taking into account the degree of sulcal effacement, severity of hydrocephalus, presence of transependymal oedema and any cerebral herniation.

**ONSD ultrasound schedule and procedure**

ONSD ultrasound was performed on days 0, 3, 7, 14, 21 and day 30 (± 1 day) after patient randomisation into ACT HIV or LAST ACT, whenever possible. Day 30 ultrasound was performed only for inpatients. ONSD ultrasound scans were performed by one of two clinicians with training in critical care ultrasound and experience of ONSD ultrasound. Preliminary data demonstrated both ultrasound operators met a pre-set acceptable inter-operative variability of 0.3mm; each operator performed the same 23 ONSD ultrasounds required to identify a 0.3mm (or greater) difference if it existed, with probability 0.9.

Ultrasound was performed using Sonosite M-Turbo (Fujifilm Sonosite Ltd, Washington, US) or Lumify (Philips, Amsterdam, Netherlands) ultrasound machines using a standard procedure. Briefly, the participant lay in bed, faced forward, looked forward, and closed their eyes. For unconscious patients, the head was gently turned to forward facing. An ultrasound probe with small volume of ultrasound gel was placed gently over the temporal portion of the upper eyelid. No pressure was applied to the eye. An image was selected where the optic nerve sheath was viewed at its widest. Imaging quality was assessed by ensuring the optic nerve sheath was seen to within 1mm of globe of eye, 6mm of continuous optic nerve was seen, and there was absence of movement artefact. At
0.3cm from the posterior border of the globe of the eye, the sheath diameter was measured. ONSD measurements were recorded twice for each eye, and then an average of all four measurements calculated.

Treatment

All participants received anti-TB chemotherapy following Vietnamese national guidelines. Rifampicin, isoniazid, pyrazinamide and ethambutol were given for at least the first 2 months of treatment, if drug resistance was not suspected or proven. Pyrazinamide was then stopped and rifampicin, isoniazid, and ethambutol were continued until 12 months anti-TB chemotherapy was received in total. Drug doses and second line regimens are described in supplementary material 2.

All participants were randomised to dexamethasone or placebo (‘study drug’), a double blinded allocation following a 1:1 randomisation (except for LTA4H TT genotype HIV uninfected participants from LAST ACT [~7% total participants] who all received dexamethasone). Study drug was administered over 8 weeks (TBM severity grade 2 or 3) or 6 weeks (TBM severity grade 1), following a tapering course, with weekly reductions (supplementary table 2). The ACT HIV and LAST ACT trials are ongoing and treatment allocations remain blinded. Results for both trials are expected to be available in 2023.

Statistical analysis

ONSD was compared with brain imaging if both were performed within a 72 hour period. Analysis populations were created by separating study participants into groups based on the presence or absence of raised ICP, and on the presence or absence of abnormal appearances, on brain MRI/CT at baseline. Median ONSD was calculated for each group given non-normal distribution of ONSD values. A sample size calculation was performed based upon non-infection brain disease[20] given limited TBM data available for this purpose. Using a 5% significance level, 90% power to detect effect size, and an expected difference in means of 1.3mm with standard deviation 1.1mm, we calculated that 15 patients were required per group (abnormal brain imaging vs. normal brain
imaging) to reject the null hypothesis if it were false. Comparison between proportions was assessed by the Chi squared test. Non-normally distributed data were compared using the Wilcoxon rank sum test. Correlation between continuous variables was performed using Spearman's rank correlation co-efficient. Data were analysed using R (version 3.6).

Results

Study population

From June 2017 to December 2019 inclusive, 107 Vietnamese adults with TBM had 267 ONSD ultrasound scans performed at day 0 (n=72), day 3 (n=48), day 7 (n=45), day 14 (n=44), day 21 (n=42) and day 30 (n=16). Four images were recorded at each of these 267 scanning time points. Median age of the study population was 37 (IQR 29-45) years. 68.2% (73/107) participants were male and 31.8% (34/107) were female. Final diagnoses of the study population were as follows; 75.7% (81/107) definite TBM, 12.1% (13/107) probable TBM, and 12.1% (13/107) possible TBM. Modified MRC TBM severity grades were; Grade 1: 33, Grade 2: n=58, Grade 3: n=16. 32.7% (35/107) participants had HIV co-infection.

Baseline ONSD associations

Baseline ONSD was performed in 67.3% (72/107) participants. Median baseline ONSD is shown by sex, final diagnosis, MRC TBM grade, and HIV co-infection status in table 2. Baseline ONSD significantly increased with more severe disease (grade 1: 0.50cm, grade 2: 0.55cm, grade 3: 0.56cm), p=0.01. HIV co-infection was not significantly associated with increased ONSD at baseline. No significant correlation was seen between baseline ONSD and baseline disease temperature, lumbar CSF opening pressure, CSF white blood cells, CSF lactate, CSF protein, or CSF/blood glucose ratio (supplementary table 3).

The association between ONSD and brain imaging
We set out to investigate whether increased ONSD correlated with brain imaging consistent with raised ICP, or with abnormal brain imaging appearances. There were 63 participants for whom ONSD and brain imaging were performed within 72 hours of each other at the start of treatment. In 6/63 participants (9.5%), brain imaging suggested raised ICP, and in 90.4% of participants (57/63), brain imaging did not suggest raised ICP. Median ONSD for the raised ICP and non-raised ICP groups were 0.55cm and 0.52cm respectively, p=0.59. In this same group of 63 participants, 39/63 participants (61.9%) had brain imaging with abnormal appearances consistent with TBM, and 38.1% of participants (24/63) had normal brain imaging. Median ONSD for the abnormal imaging and normal imaging groups were 0.55cm and 0.50cm respectively (p=0.01). Median ONSD values by brain pathology groups were as follows; hydrocephalus: 0.55cm (n=10), tuberculoma(s): 0.52cm (n=13), cerebral infarction(s): 0.55cm (n=18), meningeal enhancement: 0.52cm (n=29). To further investigate the difference in ONSD between normal and abnormal brain imaging groups, TBM severity and CSF inflammatory parameters were compared between these two groups (table 3). In the abnormal brain imaging group there were significantly elevated CSF neutrophils and CSF lactate, and significantly reduced CSF/blood glucose ratio, consistent with increased disease severity in this group.

Response to treatment, and outcomes by 3 months

Baseline ONSD was significantly higher in participants who died (0.56cm [15/72]) vs. those who survived (0.52cm [57/72]), p=0.02 (table 4). In addition, median ONSD was higher in participants who died by 3 months, vs. those who survived at 3 months, at all follow up time points (days 3,7,14,21 and 28) (figure 2).

There was no significant difference in baseline ONSD between participants who experienced neurological complications at 3 months, vs. participants who did not (0.53cm vs. 0.53cm, respectively, p=0.61). Follow up data suggested a trend of higher ONSD in participants experiencing neurological events by 3 months vs. participants without neurological events (figure 3).
A receiver operating characteristic (ROC) curve was constructed to investigate whether ONSD could predict death by 3 months (supplementary figure 1) with acceptable sensitivity and specificity. A baseline ONSD of 0.53cm or above predicted death by 3 months with 73% sensitivity and 54% specificity.

Higher ONSD values were observed in those with more severe disease (figure 4). In participants with grade 1 TBM, ONSD increases but then returns to baseline, consistent with ongoing recovery from TBM. In grade 2 and grade 3 TBM, ONSD continues to trend higher by 30 days, consistent with more severe disease in these groups.

**Discussion**

More evidence guiding the best detection and management of raised ICP in TBM is required. Point-of-care tools such as ONSD ultrasound may aid raised ICP detection in TBM, and guide management. In our study ONSD was significantly higher in participants with abnormal brain imaging compared with participants with normal brain imaging. Baseline ONSD predicted death in the first 3 months of treatment.

Neurocomplications of TBM may elevate ICP. We showed that median ONSD was significantly higher in participants with brain imaging consistent with common TBM appearances, compared with in participants with normal brain imaging. Comparison of CSF parameters between these brain imaging groups showed significantly increased median CSF neutrophil percentage and lactate, and a significantly reduced CSF/glucose ratio, in the abnormal brain imaging group vs. the normal brain imaging group. This more inflammatory CSF profile in the abnormal brain imaging group reflects an increased disease severity. However, we were unable to directly associate baseline CSF inflammatory parameters with higher baseline ONSD.

Further, baseline ONSD was significantly higher in participants who died by 3 months than in those who did not. This suggests that ONSD is elevated by brain pathology that leads to worse clinical outcomes. This correlation between ONSD and severe TBM disease leading to poor outcomes,
illustrates the potential value of ONSD in the management of TBM. Previous data have correlated ONSD and other proxy markers of raised ICP;[20] however our study is the first to associate higher ONSD with worse outcomes in TBM. In clinical practice, ONSD ultrasound therefore has the potential to enable earlier identification of neuroinflammatory complications that may progress to death, allowing prompt investigation and management. Using ROC curve analysis we identified a ‘best’ ONSD cut-off value of 0.53cm to separate participants who died by 3 months from those who survived by 3 months.

Our study has limitations. It was not possible to perform ONSD ultrasound at every time point for each participant, due to constraints on operator, participants and resources. Most scans were performed by a single operator. Whilst this allowed for consistency in scanning technique and reduced inter-operator variability, it also meant that measurement could not be reviewed by a second operator. ONSD ultrasound itself has limitations; lacking standardisation of technique and value interpretation. Additionally ONSD appearances apparently consistent with raised ICP may in fact reflect non-raised ICP pathology. Solid optic nerve sheath thickening (for example in ophthalmopathy of Graves’ disease or an optic nerve sheath meningioma), or severe orbital congestion (for example due to an arteriovenous fistula), may produce confounding appearances.[25] However, these findings are rare.

A further limitation is that we compared ONSD and brain imaging performed within 72 hours. Changes in ICP may have occurred in between ONSD ultrasound and brain imaging, reducing correlation between these two scanning modalities. The number of participants for whom radiological changes consistent with raised ICP were noted on baseline brain imaging was small, and likely why ONSD did not significantly correlate with brain imaging labelled as ‘raised ICP’. We were unable to correlate ONSD with invasively measured ICP.

Finally, it is not known if participants received corticosteroids. Participants in this study were enrolled into one of two randomised double blinded placebo-controlled trials of adjunctive
corticosteroid therapy in TBM, and the dexamethasone/placebo allocation remains unknown. Baseline data including baseline ONSD ultrasound and 3D brain imaging, prior to dexamethasone or placebo administration, were unaffected by this. Neurological complications and death at 3 months may be affected by dexamethasone; an improving individual patient ONSD trend may reflect dexamethasone use if ICP was raised due to a dexamethasone-responsive cause such as neuroinflammation. However this blinded allocation should not affect the ability of ONSD to monitor and chart this trend.

A strength of our study is that study data was collected as part of two clinical trials with study protocols, standard operating procedures, and careful conduct of research. Ours is the largest study to date of ONSD ultrasound in TBM, combining longitudinal ONSD data in individual participants with clinical endpoints. Brain imaging was independently reported by a neuroradiologist, and correlated with CSF parameters, which reflect measurements of inflammation at the site of disease, rather than correlation with blood parameters.

In conclusion we demonstrated that higher ONSD values were associated with increased disease severity, brain imaging abnormalities, and an increased risk of death by 3 months. ONSD ultrasound has potential for use as a bedside tool for ICP monitoring in TBM and identifying those at greatest risk of neurological complications and death.
NOTES

Acknowledgements

The authors would like to acknowledge the patients who participated, the doctors and nurses who cared for the patients, and the laboratory staff at the Hospital for Tropical Diseases.

Funding

This work was supported by a Wellcome Trust UK Investigator Award to Professor Guy Thwaites (110179/Z/15/Z), and by a Wellcome Trust UK Innovation for Impact in low- and middle-income countries award (WT217650/Z/19/Z). The authors declare no conflicts of interest.

The authors have no conflicts of interest to declare.
References

1. Christensen A-SH, Roed C, Omland LH, Andersen PH, Obel N, Andersen ÅB. Long-term mortality in patients with tuberculous meningitis: a Danish nationwide cohort study. PLoS One 2011; 6:e27900. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22132165. Accessed 10 February 2020.

2. Vinnard C, King L, Munsiff S, et al. Long-term Mortality of Patients With Tuberculous Meningitis in New York City: A Cohort Study. Clin Infect Dis 2016; 64:ciw763. Available at: https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciw763. Accessed 10 February 2020.

3. Thwaites GE, Bang ND, Dung NH, et al. Dexamethasone for the Treatment of Tuberculous Meningitis in Adolescents and Adults. N Engl J Med 2004; 351:1741–1751. Available at: http://www.nejm.org/doi/abs/10.1056/NEJMoa040573. Accessed 4 May 2018.

4. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013; 13:27–35. Available at: http://linkinghub.elsevier.com/retrieve/pii/S1473309912702645. Accessed 12 August 2018.

5. Cartwright C, Igbaseimokumo U. Lumbar Puncture Opening Pressure Is Not a Reliable Measure of Intracranial Pressure in Children. J Child Neurol 2015; 30:170–173. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24799366. Accessed 3 May 2018.

6. Lenfeldt N, Koskinen L-OD, Bergenheim AT, Malm J, Eklund A. CSF pressure assessed by lumbar puncture agrees with intracranial pressure. Neurology 2007; 68:155–158. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17210899. Accessed 3 May 2018.

7. Rajajee V, Vanaman M, Fletcher JJ, Jacobs TL. Optic Nerve Ultrasound for the Detection of Raised Intracranial Pressure. 2011; 15:506–515. Available at:
8. Geeraerts T, Merceron S, Benhamou D, Vigué B, Duranteau J. Non-invasive assessment of intracranial pressure using ocular sonography in neurocritical care patients. Intensive Care Med 2008; 34:2062–2067. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18509619. Accessed 2 May 2018.

9. Betcher J, Becker TK, Stoyanoff P, Cranford J, Theyyunni N. Military trainees can accurately measure optic nerve sheath diameter after a brief training session. Mil Med Res 2018; 5:42. Available at: http://www.ncbi.nlm.nih.gov/pubmed/30572931. Accessed 16 January 2019.

10. Ozgen A, Ariyurek M. Normative measurements of orbital structures using CT. Am J Roentgenol 1998; 170:1093–1096. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9530066. Accessed 3 May 2018.

11. Lee JS, Lim DW, Lee SH, Oum BS, Kim HJ, Lee HJ. Normative measurements of Korean orbital structures revealed by computerized tomography. Acta Ophthalmol Scand 2001; 79:197–200. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11284763. Accessed 3 May 2018.

12. Maude RR, Amir Hossain M, Hassan MU, et al. Transorbital Sonographic Evaluation of Normal Optic Nerve Sheath Diameter in Healthy Volunteers in Bangladesh. PloS One 2013; 8:e81013. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24312515. Accessed 3 May 2018.

13. Anas I. Transorbital sonographic measurement of normal optic sheath nerve diameter in nigerian adult population. Malays J Med Sci 2014; 21:24–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25977630. Accessed 4 May 2018.

14. Bäuerle J, Lochner P, Kaps M, Nedelmann M. Intra- and Interobsever Reliability of Sonographic Assessment of the Optic Nerve Sheath Diameter in Healthy Adults. J Neuroimaging 2012; 22:42–45. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/21121998. Accessed 3 May 2018.

15. Goeres P, Zeiler FA, Unger B, Karakitsos D, Gillman LM. Ultrasound assessment of optic nerve sheath diameter in healthy volunteers. J Crit Care 2016; 31:168–171. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26596508. Accessed 23 July 2019.

16. Wang L, Feng L, Yao Y, et al. Optimal Optic Nerve Sheath Diameter Threshold for the Identification of Elevated Opening Pressure on Lumbar Puncture in a Chinese Population. PLoS One 2015; 10:e0117939. Available at: http://dx.plos.org/10.1371/journal.pone.0117939. Accessed 3 May 2018.

17. Dubourg J, Javouhey E, Geeraerts T, Messerer M, Kassai B. Ultrasonography of optic nerve sheath diameter for detection of raised intracranial pressure: a systematic review and meta-analysis. Intensive Care Med 2011; 37:1059–1068. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21505900. Accessed 23 July 2019.

18. Robba C, Santori G, Czosnyka M, et al. Optic nerve sheath diameter measured sonographically as non-invasive estimator of intracranial pressure: a systematic review and meta-analysis. Intensive Care Med 2018; 44:1284–1294. Available at: http://link.springer.com/10.1007/s00134-018-5305-7. Accessed 22 July 2019.

19. Koziarz A, Sne N, Kegel F, et al. Bedside optic nerve ultrasonography for diagnosing increased intracranial pressure. Ann. Intern. Med. 2019; 171:896–905.

20. Sangani S, Parikh S. Can sonographic measurement of optic nerve sheath diameter be used to detect raised intracranial pressure in patients with tuberculous meningitis? A prospective observational study. Indian J Radiol Imaging 2015; 25:173. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25969641. Accessed 3 May 2018.

21. Donovan J, Phu NH, Mai NTH, et al. Adjunctive dexamethasone for the treatment of HIV-infected adults with tuberculous meningitis (ACT HIV): Study protocol for a randomised
controlled trial. Wellcome Open Res 2018; 3:31. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/30320225. Accessed 17 January 2019.

22. Donovan J, Phu NH, Thao LTP, et al. Adjunctive dexamethasone for the treatment of HIV-uninfected adults with tuberculous meningitis stratified by Leukotriene A4 hydrolase genotype (LAST ACT): Study protocol for a randomised double blind placebo controlled non-inferiority trial. Wellcome Open Res 2018; 3:32. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/30363837. Accessed 17 January 2019.

23. Wilkinson RJ, Rohlwink U, Misra UK, et al. Tuberculous meningitis. Nat Rev Neurol 2017; 13:581–598. Available at: http://www.ncbi.nlm.nih.gov/pubmed/28884751. Accessed 16 August 2018.

24. Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis 2010; 10:803–812. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/20822958. Accessed 3 May 2018.

25. Rosa N, De Bernardo M. Ultrasound assessment of optic nerve sheath diameter in healthy volunteers. J Crit Care 2017; 40:279. Available at:
https://linkinghub.elsevier.com/retrieve/pii/S0883944117303404. Accessed 23 July 2019.

26. Donovan J, Figaji A, Imran D, Phu NH, Rohlwink U, Thwaites GE. The neurocritical care of tuberculous meningitis. Lancet Neurol 2019; 18:771–783. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/31109897. Accessed 16 July 2019.
Table 1: Methods for detecting raised intracranial pressure in tuberculous meningitis [26]

| Non-invasive                                    | Invasive                                           |
|------------------------------------------------|---------------------------------------------------|
| Clinical assessment including GCS              | Lumbar CSF opening pressure                       |
| Fundoscopy                                     | Intraventricular catheters                         |
| ONSD ultrasound                                | Intraparenchymal pressure transducers              |
| Transcranial Doppler ultrasound                | Subarachnoid bolts                                |
| Brain imaging (CT or MRI)                      | Epidural transducers                               |

CSF=Cerebrospinal fluid. CT=Computed tomography. GCS=Glasgow coma score. MRI=Magnetic resonance imaging. ONSD=Optic nerve heath diameter.
Table 2: Median baseline ONSD by sub-categories

|                          | Total No. (N=72) | Median ONSD (cm) | P value |
|--------------------------|------------------|------------------|---------|
| All patients             | 72               | 0.53             |         |
| Sex                      |                  |                  |         |
| - Male (No [%])          | 47 (65.3%)       | 0.52             | 0.89    |
| - Female (No [%])        | 25 (34.7%)       | 0.54             |         |
| Final diagnosis (No [%]) |                  |                  |         |
| - Definite TBM           | 53 (73.6%)       | 0.54             | 0.25*   |
| - Probable TBM           | 7 (9.7%)         | 0.52             |         |
| - Possible TBM           | 12 (16.7%)       | 0.51             |         |
| MRC TBM Grade (No [%])   |                  |                  |         |
| - 1                      | 23 (31.9%)       | 0.50             | 0.01 #  |
| - 2                      | 39 (54.2%)       | 0.55             |         |
| - 3                      | 10 (13.9%)       | 0.56             |         |
| HIV status (No [%])      |                  |                  |         |
| - Positive               | 20 (27.8%)       | 0.56             | 0.17    |
| - Negative               | 52 (72.2%)       | 0.52             |         |
* Definite TBM compared with non-definite. * Grade 1 compared with grades 2 & 3. Two final diagnoses scoring as ‘Not TBM’ with the uniform case definition[24] were converted to ‘Possible TBM’ on the basis that clinical diagnosis was of TBM, and anti-TB chemotherapy was received.

The Wilcoxon rank sum test was used to compare ONSD values. Total No. reflects the total number of observations available for the corresponding variable. Medical Research Council grades are as follows: Grade 1 indicates a GCS of 15 with no neurological signs, grade 2 a GCS of 11 to 14 (or 15 with focal neurological signs), and grade 3 a GCS of 10 or less.

HIV=Human immunodeficiency virus. MRC= Medical Research Council. ONSD=Optic nerve sheath diameter. TBM=Tuberculous meningitis.
Table 3: Disease severity and CSF inflammatory parameters for normal and abnormal brain imaging groups

|                | Total No. | Normal brain imaging (N=24) | Total No. | Abnormal brain imaging (N=39) | P value |
|----------------|-----------|----------------------------|-----------|-------------------------------|---------|
| **Age** (Median[IQR]) | 24 | 41 (28-50) | 39 | 34 (29-40) | 0.08 |
| **Sex** | 24 | 16 (66.7%) | 39 | 25 (64.1%) | 1.0 |
| - Male (No [%]) | 24 | 12 (50%) | 39 | 10 (25.6%) | 0.09* |
| - Female (No [%]) | 24 | 11 (45.8%) | 39 | 25 (64.1%) | 0.09* |
| - MRC TBM Grade (No [%]) | 24 | 1 (4.2%) | 39 | 4 (10.3%) | 1.0 |
| - 1 | 24 | 6 (25%) | 39 | 9 (23.1%) | 1.0 |
| - 2 | 24 | 18 (75%) | 39 | 30 (76.9%) | 1.0 |
| - HIV status (No [%]) | 24 | 18 (75%) | 39 | 26 (67.2%) | 0.31 |
| - Positive | 24 | 6 (25%) | 39 | 9 (23.1%) | 0.31 |
| - Negative | 24 | 18 (75%) | 39 | 30 (76.9%) | 0.31 |
| **Highest temperature (°C)** (Median[IQR]) | 24 | 38.7 (38.0-39.5) | 39 | 39.0 (38.7-39.5) | 0.54 |
| **Lumbar CSF opening pressure (cmH₂O)** | 15 | 18 | 26 | 20 | 0.54 |
| Test                          | Median/IQR          | Grade 1 | Grade 2 | Grade 3 | P-value |
|-------------------------------|---------------------|---------|---------|---------|---------|
| CSF WBC (cells/mm³)          | 24/283 (137-501)    | 39/304  | 0.32    |
| CSF neutrophil %             | 23/13 (11-30)       | 39/48   | 0.002   |
| CSF neutrophil count         | 23/43 (19-120)      | 39/142  | 0.01    |
| CSF/blood glucose ratio      | 24/0.39 (0.24-0.44) | 39/0.27 | 0.02    |
| CSF lactate (mmol/L)         | 24/4.0 (3.0-5.7)    | 39/5.8  | 0.001   |

* Grade 1 compared with grades 2 & 3. The Wilcoxon rank sum test and Chi squared test were used to compare averages of continuous and categorical data, respectively. Highest temperature, lumbar CSF opening pressure, CSF WBC, CSF neutrophil percentage, CSF/blood glucose ratio and CSF lactate are non-normally distributed and are shown as median (IQR).

CSF=Cerebrospinal fluid. HIV=Human immunodeficiency virus. IQR=Interquartile range.

MRC=Medical Research Council. TBM=Tuberculous meningitis. WBC=White blood cells.
Table 4: Median baseline ONSD by clinical endpoints

| Neurological complication by 3 months (No. [%]) | Total No. (N=72) | Median ONSD (cm) | P value |
|-----------------------------------------------|------------------|------------------|---------|
| - Yes                                         | 12 (16.7%)       | 0.53             | 0.61    |
| - No                                          | 60 (83.3%)       | 0.53             |         |

| Death by 3 months (No. [%])                  | Total No. (N=72) | Median ONSD (cm) | P value |
|----------------------------------------------|------------------|------------------|---------|
| - Yes                                        | 15 (20.8%)       | 0.56             | 0.02    |
| - No                                         | 57 (79.2%)       | 0.52             |         |

P values represent comparison for ONSD values by the Wilcoxon rank sum test. Total No reflects the total number of observations available for the corresponding variable. Medical Research Council grades are as follows: Grade 1 indicates a GCS of 15 with no neurological signs, grade 2 a GCS of 11 to 14 (or 15 with focal neurological signs), and grade 3 a GCS of 10 or less. ONSD=Optic nerve sheath diameter.
FIGURE LEGENDS

Figure 1: Distended optic nerve sheath consistent with raised ONSD

Ultrasound images of the right eye are shown with, (panel A) and without, (panel B) descriptive labels. The borders of the optic nerve sheath are marked with a dotted line in panel A. In panel C a diagram is shown illustrating the appearances seen under ultrasound, showing how these appearances relate to patient position, CSF spaces (yellow) and optic nerve (blue). ONSD measured 0.3cm from the posterior border of the globe of the eye was 0.74cm. ONSD is measured as the distance inside the dura mater. CSF=Cerebrospinal fluid. ONSD=Optic nerve sheath diameter.

Figure 2: ONSD over 30 days of anti-TB chemotherapy, stratified by death by 3 months

For each individual boxplot, the central horizontal bar represents the median value. The box contains data between 3rd quartile (upper end of box) and 1st quartile (lower end of box). Vertical lines above and below each box extend to the most extreme data point that is within 1.5x the vertical height of the box. Dots represent individual data points outside of these limits. P values represent statistical comparison of ONSD values performed by the Wilcoxon rank sum test. ONSD=Optic nerve sheath diameter. TB=Tuberculosis.
Figure 3: ONSD over 30 days of anti-TB chemotherapy, stratified by neurological complications by 3 months

For each individual boxplot, the central horizontal bar represents the median value. The box contains data between 3rd quartile (upper end of box) and 1st quartile (lower end of box). Vertical lines above and below each box extend to the most extreme data point that is within 1.5x the vertical height of the box. Dots represent individual data points outside of these limits. P values represent statistical comparison of ONSD values performed by the Wilcoxon rank sum test. ONSD=Optic nerve sheath diameter. TB=Tuberculosis.

Figure 4: ONSD values over 30 days of anti-TB chemotherapy, stratified by TBM severity grade and death by 3 months

Individual data points represent individual ONSD values at a specified day of measurement. Data are shown stratified by grade 1, 2 and 3, where grade refers to MRC TBM severity grade Blue dots represent ONSD values in patients who were alive by 3 months, whereas red dots represent ONSD values in patients who died by 3 months. The mean ONSD value across time points, for each grade, is represented by a green line with associated 95% CI. CI=Confidence interval. MRC=Medical Research Council. ONSD=Optic nerve sheath diameter. TBM=Tuberculous meningitis.
Figure 2
Figure 3

The image displays a box plot showing the distribution of ONSD (Optic Nerve Sheath Diameter) values over different days of measurement. The x-axis represents the day of ONSD measurement, ranging from 0 to 28 days. The y-axis shows the ONSD value in cm, ranging from 0.4 to 0.8 cm.

The plot includes two groups: patients with and without neurological complications by 3 months. Each group is represented by different colors and symbols. The significance levels (p-values) are indicated above the x-axis for each group, with p-values ranging from 0.01 to 0.9.

The box plots indicate the median, interquartile range, and outliers for each group. The comparisons suggest there are no significant differences in ONSD values between the two groups.

Key observations:
- The median ONSD value for patients with neurological complications by 3 months is slightly higher than for those without.
- There is a trend of decreasing ONSD values over time for both groups.
- No significant differences were observed between the groups at any of the measurement days.

Neurological complications by 3 months:
- No
- Yes
